|
|
|
|
|
|
|
|
|
22.12.25 - 12:48
|
Cytokinetics receives FDA approval for MYQORZO tablets for oHCM (PBR)
|
|
|
In patients suffering with oHCM, myosin inhibition with MYQORZO, which is an allosteric and reversible inhibitor of cardiac myosin motor activity, lowers left ventricular outflow tract (LVOT) obstruction
The post Cytokinetics receives FDA approval for MYQORZO tablets for oHCM appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
19.12.25 - 20:18
|
XFRA: KK3A: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
CYTOKINETICS INC. DL-,001 KK3A US23282W6057 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
16.12.25 - 22:03
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire EN)
|
|
|
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in November and December 2025 as a material inducement to their employment....
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
